GTC
OREX

Ghost Tree Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Ghost Tree Capital’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-25,000
Closed -$1.54M – 96
2014
Q2 		$1.54M Buy
+25,000
New +$1.45M 1.09% 34

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ghost Tree Capital's OREX Position: Q3 2014 in Review

Ghost Tree Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 25,000 shares — an estimated $1.54M sold.

Ghost Tree Capital first reported a position in OREX in Q2 2014 and held it in 1 quarter. The position peaked at $1.54M in Q2 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

  • Ghost Tree Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Ghost Tree Capital sold 25,000 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $1.54M.
  • Ghost Tree Capital first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Ghost Tree Capital's Orexigen Therapeutics, Inc. position peaked at $1.54M in Q2 2014.
  • 128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Ghost Tree Capital's 13F filing for Q3 2014, filed 14 Nov 2014.